CD52 inhibits Toll-like receptor activation of NF-κB and triggers apoptosis to suppress inflammation

Soluble CD52 is a small glycoprotein that suppresses T-cell activation, but its effect on innate immune cell function is unknown. Here we demonstrate that soluble CD52 inhibits Toll-like receptor and tumor necrosis factor receptor signaling to limit activation of NF- κ B and thereby suppress the pro...

Full description

Saved in:
Bibliographic Details
Published inCell death and differentiation Vol. 25; no. 2; pp. 392 - 405
Main Authors Rashidi, Maryam, Bandala-Sanchez, Esther, Lawlor, Kate E, Zhang, Yuxia, Neale, Alana M, Vijayaraj, Swarna L, O'Donoghue, Robert, Wentworth, John M, Adams, Timothy E, Vince, James E, Harrison, Leonard C
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.02.2018
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Soluble CD52 is a small glycoprotein that suppresses T-cell activation, but its effect on innate immune cell function is unknown. Here we demonstrate that soluble CD52 inhibits Toll-like receptor and tumor necrosis factor receptor signaling to limit activation of NF- κ B and thereby suppress the production of inflammatory cytokines by macrophages, monocytes and dendritic cells. At higher concentrations, soluble CD52 depletes the short-lived pro-survival protein MCL-1, contributing to activation of the BH3-only proteins BAX and BAK to cause intrinsic apoptotic cell death. In vivo , administration of soluble CD52 suppresses lipopolysaccharide (LPS)-induced cytokine secretion and other features of endotoxic shock, whereas genetic deletion of CD52 exacerbates LPS responses. Thus, soluble CD52 exhibits broad immune suppressive effects that signify its potential as an immunotherapeutic agent.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
Current address: Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria 3084, Australia.
Current address: Guangzhou Women and Children Medical Center, Guangzhou, China.
ISSN:1350-9047
1476-5403
DOI:10.1038/cdd.2017.173